Searchable abstracts of presentations at key conferences in endocrinology

ea0048o7 | Oral Communications | SFEEU2017

Hypertestosteronemia and primary infertility due to an extragonadal germ cell tumor of the anterior mediastinum

Dimitriadis Georgios K , Kaltsas Gregory , Randeva Harpal S

A 26-year-old Caucasian male presented to the joint infertility outpatients clinic with primary infertility. His medical history included hypertrophic cardiomyopathy (HCM) due to genetically confirmed MYH7 sarcomere protein mutation, treated with implantable cardioverter-defibrillator while his partner was a healthy 24-year-old Caucasian nulliparous female. Initial investigations showed hypertestosteronemia (Testosterone: >51.0 nmol/l) and azoospermia, hence the c...

ea0074ncc13 | Highlighted Cases | SFENCC2021

Refractory Graves’ disease following total thyroidectomy caused by concurrent ectopic thyroid tissue in the anterior mediastinum

Sathyanarayan Sheela , Li Adrian , Arshad Sobia , Dimitriadis Georgios K

Case History :A 34-year-old Caucasian female patient presented in May 2015 to A&E with symptoms of overt thyroid dysfunction. She was managed medically until June 2016 when thionamide treatment was withdrawn. Unfortunately, this lady had a first disease relapse in July 2018 whilst she was pregnant at 35 weeks of gestation and then further disease relapse in January 2020 during her second pregnancy. Investigations: Initial biochemistry in 2015 confirm...

ea0050p336 | Obesity and Metabolism | SFEBES2017

Metabolic phenotype of Male Obesity-associated Secondary Hypogonadism pre- and post-replacement therapy with intra-muscular Testosterone undecanoate therapy

Dimitriadis Georgios K , Randeva Harpal S , Grammatopoulos Dimitris K , Barber Thomas M

Aim: To explore the metabolic phenotype of Male Obesity-associated Secondary Hypogonadism (MOSH) and following treatment with long-acting intramuscular (IM) testosterone undecanoate.Methods: A prospective observational pilot study on metabolic effects of IM testosterone undecanoate in MOSH (Hypogonadal [HG] group, n=13), including baseline comparisons with controls (Eugonadal [EG] group, n=15). Half the subj...

ea0050p336 | Obesity and Metabolism | SFEBES2017

Metabolic phenotype of Male Obesity-associated Secondary Hypogonadism pre- and post-replacement therapy with intra-muscular Testosterone undecanoate therapy

Dimitriadis Georgios K , Randeva Harpal S , Grammatopoulos Dimitris K , Barber Thomas M

Aim: To explore the metabolic phenotype of Male Obesity-associated Secondary Hypogonadism (MOSH) and following treatment with long-acting intramuscular (IM) testosterone undecanoate.Methods: A prospective observational pilot study on metabolic effects of IM testosterone undecanoate in MOSH (Hypogonadal [HG] group, n=13), including baseline comparisons with controls (Eugonadal [EG] group, n=15). Half the subj...

ea0086p330 | Metabolism, Obesity and Diabetes | SFEBES2022

Glicentin concentrations following Liraglutide treatment in patients with overweight/obesity

Al-Hasani Wiaam , Ranasinghe Ruvini , Luxton James , Mare Tracey , Dimitriadis Georgios K , Vincent Royce P

Background: Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist that promotes weight loss. The minimum adequate/good response to liraglutide (≥5% weight loss at 3 months) is not achievable in all patients. Currently there are no biomarkers to predict good response. Enhanced postprandial glicentin concentration was recently considered as superior to GLP-1 in predicting weight loss following bariatric surgeries.Objective 1) T...

ea0050p224 | Diabetes and Cardiovascular | SFEBES2017

UHCW audit on SGLT2 inhibitor (SGLT2-i) use

Mytilinaiou Maria , Dimitriadis Georgios K , Davasgaium Allan , Sambrook Diane , Hewins Claire , Nalawade Nilisha , Grammatopoulos Dimitris K , Randeva Harpal S

Aim: After almost 2 centuries, SGLT2-i have made their comeback in human pharmacology through successful re-introduction in diabetes type 2 (T2D). Via restriction of renal glucose reabsorption, SGLT2-i have shown promising results. The aim of this audit was to ensure that current practice at UHCW NHS Trust is in line with the agreed national standards, whilst collecting clinical data from the use of SGLT2-i.Methods: This...

ea0050ep061 | Neoplasia, Cancer and Late Effects | SFEBES2017

Hypertestosteronemia and primary infertility from a mediastinal extragonadal germ cell tumor

Dimitriadis Georgios K , Mytilinaiou Maria , Davasgaium Allan , Sambrook Diane , Drakou Eftychia E , Hewins Claire , Nalawade Nilisha , Randeva Harpal S

A 26-year-old Caucasian male presented to the joint infertility outpatients clinic with primary infertility. His medical history included hypertrophic cardiomyopathy (HCM) due to genetically confirmed MYH7 sarcomere protein mutation, treated with implantable cardioverter-defibrillator while his partner was a healthy 24-year-old Caucasian nulliparous female. Initial investigations showed hypertestosteronemia (Testosterone: >...

ea0050p224 | Diabetes and Cardiovascular | SFEBES2017

UHCW audit on SGLT2 inhibitor (SGLT2-i) use

Mytilinaiou Maria , Dimitriadis Georgios K , Davasgaium Allan , Sambrook Diane , Hewins Claire , Nalawade Nilisha , Grammatopoulos Dimitris K , Randeva Harpal S

Aim: After almost 2 centuries, SGLT2-i have made their comeback in human pharmacology through successful re-introduction in diabetes type 2 (T2D). Via restriction of renal glucose reabsorption, SGLT2-i have shown promising results. The aim of this audit was to ensure that current practice at UHCW NHS Trust is in line with the agreed national standards, whilst collecting clinical data from the use of SGLT2-i.Methods: This...

ea0050ep061 | Neoplasia, Cancer and Late Effects | SFEBES2017

Hypertestosteronemia and primary infertility from a mediastinal extragonadal germ cell tumor

Dimitriadis Georgios K , Mytilinaiou Maria , Davasgaium Allan , Sambrook Diane , Drakou Eftychia E , Hewins Claire , Nalawade Nilisha , Randeva Harpal S

A 26-year-old Caucasian male presented to the joint infertility outpatients clinic with primary infertility. His medical history included hypertrophic cardiomyopathy (HCM) due to genetically confirmed MYH7 sarcomere protein mutation, treated with implantable cardioverter-defibrillator while his partner was a healthy 24-year-old Caucasian nulliparous female. Initial investigations showed hypertestosteronemia (Testosterone: >...

ea0063p1025 | Interdisciplinary Endocrinology 2 | ECE2019

In vitro study of Orexin alpha effects on factors involved in atherosclerosis: a dual role?

Karapanagioti Angeliki , Spenzta Flora , Dimitriadis Georgios K. , Nasiri-Ansari Narjes , Lianidou Evi , Papavassiliou Athanasios G , Randeva Harpal S , Kassi Eva

Introduction: Malnutrition in neonates and children has been associated with adult-onset diseases such as obesity and atherosclerosis. Infants breastfeeding exhibit a different pattern of orexin-α secretion compared to formula-fed or infants on parenteral feeding. Given the protective role of maternal milk in the onset of metabolic syndrome and atherosclerosis in later life, we hypothesized that orexin-α may be involved in this process. We studied in vitro t...